Literature DB >> 23536672

A novel PCR assay for quantification of HIV-1 RNA.

Liang Shan1, S Alireza Rabi, Gregory M Laird, Evelyn E Eisele, Hao Zhang, Joseph B Margolick, Robert F Siliciano.   

Abstract

Current assays for quantification of HIV-1 virions rely on real-time reverse transcriptase (RT)-PCR detection of conserved regions of HIV-1 RNA and can be limited by detection of contaminating viral or plasmid DNA. We developed a novel RT-PCR assay using a reverse primer that hybridizes with the poly(A) tail of HIV-1 mRNAs, anchored by conserved viral nucleotides at the most distal region of the transcript. This assay can detect and quantify HIV-1 RNA with high specificity and sensitivity.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23536672      PMCID： PMC3648108          DOI： 10.1128/JVI.00006-13

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  25 in total

1.  Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.

Authors:  Yefei Han; Kara Lassen; Daphne Monie; Ahmad R Sedaghat; Shino Shimoji; Xiao Liu; Theodore C Pierson; Joseph B Margolick; Robert F Siliciano; Janet D Siliciano
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Authors:  Richard E Nettles; Tara L Kieffer; Patty Kwon; Daphne Monie; Yefei Han; Teresa Parsons; Joseph Cofrancesco; Joel E Gallant; Thomas C Quinn; Brooks Jackson; Charles Flexner; Kathryn Carson; Stuart Ray; Deborah Persaud; Robert F Siliciano
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

3.  Transcriptional interference antagonizes proviral gene expression to promote HIV latency.

Authors:  Tina Lenasi; Xavier Contreras; B Matija Peterlin
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

4.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Authors:  Sarah Palmer; Frank Maldarelli; Ann Wiegand; Barry Bernstein; George J Hanna; Scott C Brun; Dale J Kempf; John W Mellors; John M Coffin; Martin S King
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

5.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Authors:  J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

6.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.

Authors:  A Lever; H Gottlinger; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Authors:  Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

8.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

9.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  HIV-1 Tat protein promotes formation of more-processive elongation complexes.

Authors:  R A Marciniak; P A Sharp
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598
View more
  53 in total

Review 1.  Measuring the latent reservoir in vivo.

Authors:  Marta Massanella; Douglas D Richman
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

2.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.

Authors:  Hiromi Imamichi; Robin L Dewar; Joseph W Adelsberger; Catherine A Rehm; Una O'Doherty; Ellen E Paxinos; Anthony S Fauci; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

3.  Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.

Authors:  Ross A Pollack; R Brad Jones; Mihaela Pertea; Katherine M Bruner; Alyssa R Martin; Allison S Thomas; Adam A Capoferri; Subul A Beg; Szu-Han Huang; Sara Karandish; Haiping Hao; Eitan Halper-Stromberg; Patrick C Yong; Colin Kovacs; Erika Benko; Robert F Siliciano; Ya-Chi Ho
Journal:  Cell Host Microbe       Date:  2017-04-12       Impact factor: 21.023

4.  Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

Authors:  S Alireza Rabi; Gregory M Laird; Christine M Durand; Sarah Laskey; Liang Shan; Justin R Bailey; Stanley Chioma; Richard D Moore; Robert F Siliciano
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

5.  Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus.

Authors:  Laura J Martins; Pawel Bonczkowski; Adam M Spivak; Ward De Spiegelaere; Camille L Novis; Ana Beatriz DePaula-Silva; Eva Malatinkova; Wim Trypsteen; Alberto Bosque; Linos Vanderkerckhove; Vicente Planelles
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-14       Impact factor: 2.205

6.  Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.

Authors:  Gregory M Laird; C Korin Bullen; Daniel I S Rosenbloom; Alyssa R Martin; Alison L Hill; Christine M Durand; Janet D Siliciano; Robert F Siliciano
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

Review 7.  Barriers for HIV Cure: The Latent Reservoir.

Authors:  Sergio Castro-Gonzalez; Marta Colomer-Lluch; Ruth Serra-Moreno
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-28       Impact factor: 2.205

8.  No recovery of replication-competent HIV-1 from human liver macrophages.

Authors:  Abraham J Kandathil; Sho Sugawara; Ashish Goyal; Christine M Durand; Jeffrey Quinn; Jaiprasath Sachithanandham; Andrew M Cameron; Justin R Bailey; Alan S Perelson; Ashwin Balagopal
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

9.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

10.  Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.

Authors:  Wen Peng; Zhongsi Hong; Xi Chen; Hongbo Gao; Zhuanglin Dai; Jiacong Zhao; Wen Liu; Dan Li; Kai Deng
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.